OVID
Ovid Therapeutics Inc.
$2.30
+4.07%
$429.3M
No data for this timeframe.
Vol
Market Cap$429.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders44 funds
Inst. Value$121.0M
Inst. Activity8 buys / 4 sells
Insider Activity0B / 2S
Insider Net $-$29.3K
SEC Reports7
Press Releases2
Recent Activity
Jun 11, 2026
short_volume
Short Volume: OVID — 58.4% short (0.7M / 1.2M)
Short: 689,364 | Exempt: 14,397 | TRF Vol: 1,180,976 | Short Ratio: 58.4% | Off-exchange volume (dar
Jun 3, 2026
SEC
Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute executive, as a Class
8-K — Impact 2/10
May 12, 2026
SEC
Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a
PRESS-RELEASE — Impact 6/10
Apr 27, 2026
SEC
Ovid Therapeutics' shelf registration (S-3) has become effective, allowing the company and selling stockholders to offer
EFFECT — Impact 4/10
Apr 7, 2026
Insider
Fitzgerald Kevin Joseph was granted 17,578 shares
Director @ $2.56 ($45.0K)
Apr 7, 2026
Insider
Friedman Bart was granted 8,789 shares
Director @ $2.56 ($22.5K)
Apr 7, 2026
Insider
PAPADOPOULOS STELIOS was granted 17,578 shares
Director @ $2.56 ($45.0K)
Inst.
JANUS HENDERSON GROUP PLC — NEW
10,714,000 shares ($23.7M)
Price Targets
$5.47
+137.9% upside
Strong Buy
Current $2.30
Low $4.00
Median $5.00
High $7.00
9 analysts
$4.00
$7.00
Analyst Ratings
7Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 15, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Apr 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 26, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 20, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Dec 22, 2025 | LifeSci Capital | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.10 | $-0.12 — $-0.10 | -74% YoY | 7 |
| Next Q | $-0.11 | $-0.13 — $-0.09 | 38% YoY | 7 |
| Current FY | $-0.44 | $-0.49 — $-0.40 | -91% YoY | 7 |
| Next FY | $-0.45 | $-0.56 — $-0.35 | -3% YoY | 6 |
Latest Reports
NEUTRAL
8-K
2/10
Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute executive, as a Class
Jun 3, 2026
MIXED
PRESS-RELEASE
6/10
Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) versus $10.2M loss a
May 12, 2026
MIXED
Press
6/10
Ovid Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a $9.7 million net income in Q4 drive
Mar 18, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $23.8M | NEW |
| JANUS HENDERSON GROUP PLC | $23.7M | NEW |
| ADAGE CAPITAL PARTNERS GP, | $13.7M | ADD |
| BALYASNY ASSET MANAGEMENT L.P. | $12.3M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $11.7M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 7, 2026 | Fitzgerald Kevin | A | $45.0K |
| Apr 7, 2026 | Friedman Bart | A | $22.5K |
| Apr 7, 2026 | PAPADOPOULOS STELIOS | A | $45.0K |
| Mar 23, 2026 | LEVIN JEREMY | M | $66.3K |
| Feb 26, 2026 | PAPADOPOULOS STELIOS | A | $0.00 |
44 institutional holders with $121.0M total value (54,530,598 shares) as of 2026-Q1. Top holders: RA, JANUS, ADAGE. Net buying activity: 8 institutions added/increased vs 4 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 10,714,000 | $23.8M | 19.7% | NEW |
| 2 | JANUS HENDERSON GROUP PLC | 10,714,000 | $23.7M | 19.6% | NEW |
| 3 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6,163,781 | $13.7M | 11.3% | ADD +76.5% |
| 4 | BALYASNY ASSET MANAGEMENT L.P. | 5,533,073 | $12.3M | 10.2% | DOUBLED +1602.5% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 5,258,246 | $11.7M | 9.6% | — |
| 6 | FEDERATED HERMES, INC. | 3,571,000 | $7.9M | 6.6% | — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,947,594 | $4.3M | 3.6% | — |
| 8 | BlackRock, Inc. | 1,533,283 | $3.4M | 2.8% | DOUBLED +149.9% |
| 9 | Point72 Asset Management, L.P. | 1,320,610 | $2.9M | 2.4% | TRIM -62.8% |
| 10 | TWO SIGMA INVESTMENTS, LP | 1,256,869 | $2.8M | 2.3% | ADD +75.6% |
| 11 | RENAISSANCE TECHNOLOGIES LLC | 1,104,300 | $2.5M | 2.0% | TRIM -25.6% |
| 12 | MARSHALL WACE, LLP | 917,733 | $2.0M | 1.7% | TRIM -27.8% |
| 13 | WELLS FARGO & COMPANY/MN | 713,625 | $1.6M | 1.3% | — |
| 14 | VANGUARD FIDUCIARY TRUST CO | 693,256 | $1.5M | 1.3% | — |
| 15 | STATE STREET CORP | 520,283 | $1.2M | 1.0% | ADD +88.1% |
| 16 | CITADEL ADVISORS LLC | 367,902 | $816.7K | 0.7% | — |
| 17 | SEI INVESTMENTS CO | 328,924 | $730.2K | 0.6% | — |
| 18 | BANK OF AMERICA CORP /DE/ | 290,432 | $644.8K | 0.5% | ADD +49.0% |
| 19 | CIBC WORLD MARKET INC. | 249,351 | $553.6K | 0.5% | — |
| 20 | Assenagon Asset Management S.A. | 227,742 | $505.6K | 0.4% | TRIM -63.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | NEW | — | 10,714,000 | — | $23.7M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 3,492,000 | 6,163,781 | +76.5% | $13.7M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | DOUBLED | 325,000 | 5,533,073 | +1602.5% | $12.3M | 2026-Q1 |
| BlackRock, Inc. | DOUBLED | 613,475 | 1,533,283 | +149.9% | $3.4M | 2026-Q1 |
| Point72 Asset Management, L.P. | TRIM | 3,551,129 | 1,320,610 | -62.8% | $2.9M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,484,478 | 1,104,300 | -25.6% | $2.5M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 1,271,487 | 917,733 | -27.8% | $2.0M | 2026-Q1 |
| STATE STREET CORP | ADD | 276,533 | 520,283 | +88.1% | $1.2M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 194,900 | 290,432 | +49.0% | $644.8K | 2026-Q1 |
| Assenagon Asset Management S.A. | TRIM | 618,019 | 227,742 | -63.1% | $505.6K | 2026-Q1 |
| Invesco Ltd. | DOUBLED | 33,308 | 101,581 | +205.0% | $225.5K | 2026-Q1 |
| MORGAN STANLEY | ADD | 36,952 | 49,555 | +34.1% | $110.0K | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 10,714,000 | — | $17.5M | 2025-Q4 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 1,350,000 | 3,492,000 | +158.7% | $5.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,018,024 | 1,484,478 | -26.4% | $2.4M | 2025-Q4 |
| MARSHALL WACE, LLP | ADD | 783,653 | 1,271,487 | +62.3% | $2.1M | 2025-Q4 |
| Assenagon Asset Management S.A. | TRIM | 924,576 | 618,019 | -33.2% | $1.0M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 341,134 | 598,869 | +75.6% | $976.2K | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 625,000 | 325,000 | -48.0% | $529.8K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 362,707 | 194,900 | -46.3% | $317.7K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 2,314 | 36,952 | +1496.9% | $60.2K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 1,506 | 23 | -98.5% | — | 2025-Q3 |
| Assenagon Asset Management S.A. | DOUBLED | 435,620 | 924,576 | +112.2% | $1.2M | 2025-Q3 |
| MARSHALL WACE, LLP | DOUBLED | 164,721 | 783,653 | +375.7% | $1.0M | 2025-Q3 |
| BlackRock, Inc. | TRIM | 1,369,010 | 611,315 | -55.3% | $794.7K | 2025-Q3 |
8 unique insiders with 15 transactions. Net insider value: -$29.3K ($0.00 bought, $29.3K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 7, 2026 | Fitzgerald Kevin Joseph | Director | AWARD | 17,578 | $2.56 | $45.0K |
| Apr 7, 2026 | Friedman Bart | Director | AWARD | 8,789 | $2.56 | $22.5K |
| Apr 7, 2026 | PAPADOPOULOS STELIOS | Director | AWARD | 17,578 | $2.56 | $45.0K |
| Mar 23, 2026 | LEVIN JEREMY M | Executive Chairman | EXERCISE | 47,333 | $1.40 | $66.3K |
| Feb 26, 2026 | PAPADOPOULOS STELIOS | Director | AWARD | 65,000 | — | — |
| Feb 26, 2026 | LEVIN JEREMY M | Director | AWARD | 957,000 | — | — |
| Feb 26, 2026 | Fitzgerald Kevin Joseph | Director | AWARD | 65,000 | — | — |
| Feb 26, 2026 | Friedman Bart | Director | AWARD | 65,000 | — | — |
| Feb 26, 2026 | DUNCAN BARBARA GAYLE | Director | AWARD | 65,000 | — | — |
| Feb 26, 2026 | Bernstein Karen | Director | AWARD | 65,000 | — | — |
| Feb 26, 2026 | Rona Jeffrey A | CBFO | AWARD | 68,125 | — | — |
| Feb 26, 2026 | Rona Jeffrey A | CBFO | AWARD | 408,750 | — | — |
| Feb 26, 2026 | ALEXANDER MARGARET A. | President and CEO | AWARD | 1,435,000 | — | — |
| Feb 23, 2026 | ALEXANDER MARGARET A. | President and CEO | SELL | 11,656 | $1.45 | $16.9K |
| Feb 23, 2026 | Rona Jeffrey A | CBFO | SELL | 8,541 | $1.45 | $12.4K |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
2/10
Ovid Therapeutics appointed Dr. Anna Greka, a Harvard Medical School professor and Broad Institute e
Jun 3, 2026
MIXED
PRESS-RELEASE
6/10
Ovid Therapeutics reported Q1 2026 financial results featuring a net loss of $17.0M (-$0.12/share) v
May 12, 2026
NEUTRAL
EFFECT
4/10
Ovid Therapeutics' shelf registration (S-3) has become effective, allowing the company and selling s
Apr 27, 2026
NEUTRAL
S-3
4/10
Ovid Therapeutics has filed a shelf registration (S-3) to allow selling stockholders to resell up to
Apr 21, 2026
BULLISH
8-K
6/10
Ovid Therapeutics Inc. announced that its Series A Warrants expired on April 17, 2026, resulting in
Apr 20, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K filing includes e
Mar 18, 2026
NEUTRAL
CLUSTER
2/10
Ovid Therapeutics' Chief Business and Financial Officer, Rona Jeffrey A, was granted 68,125 shares a
Mar 2, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 7 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$5.47 mean target
+137.9% upside
Strong Buy (3.00)
$4.00 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $2.30 |
| Target Low | $4.00 |
| Target Mean | $5.47 |
| Target Median | $5.00 |
| Target High | $7.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.10 | $-0.12 | $-0.10 | -73.8% | — | 0↑ 4↓ | $0.0B | -100.0% | 7 |
| Next Q 2026-09-30 |
$-0.11 | $-0.13 | $-0.09 | 37.8% | — | 1↑ 3↓ | $0.0B | -88.9% | 7 |
| Current FY 2026-12-31 |
$-0.44 | $-0.49 | $-0.40 | -91.3% | — | 2↑ 5↓ | $0.0B | -98.5% | 7 |
| Next FY 2027-12-31 |
$-0.45 | $-0.56 | $-0.35 | -2.7% | — | 2↑ 3↓ | $0.0B | 55.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.104 | |
| 7d ago | $-0.105 | +0.001 |
| 30d ago | $0.000 | -0.104 |
| 60d ago | $-0.105 | +0.001 |
| 90d ago | $-0.078 | -0.026 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 15, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Apr 9, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 26, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 20, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Dec 22, 2025 | LifeSci Capital | INITIATE | — | Outperform |
| Dec 22, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 7 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 11, 2026
short_volume
Short Volume: OVID — 58.4% short (0.7M / 1.2M)
Short: 689,364 | Exempt: 14,397 | TRF Vol: 1,180,976 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: OVID — 56.9% short (0.4M / 0.8M)
Short: 430,898 | Exempt: 560 | TRF Vol: 756,810 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Jun 4, 2026
other
Ovid Therapeutics to Participate in Upcoming Investor Conferences
<p align="justify">NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pione
Jun 3, 2026
other
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
<p align="justify">NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pione
Jun 1, 2026
short_volume
Short Volume: OVID — 60.8% short (0.7M / 1.1M)
Short: 659,648 | Exempt: 0 | TRF Vol: 1,084,893 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: OVID — 61.6% short (0.4M / 0.6M)
Short: 363,079 | Exempt: 812 | TRF Vol: 589,599 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: OVID — 58.0% short (0.4M / 0.7M)
Short: 398,953 | Exempt: 2,020 | TRF Vol: 687,419 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: OVID — 62.3% short (0.4M / 0.6M)
Short: 398,430 | Exempt: 317 | TRF Vol: 639,468 | Short Ratio: 62.3% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings_calendar
OVID Q1 2026 Earnings Scheduled — 2026-05-13
May 12, 2026
earnings
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
<p align="justify"><br>NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pi
May 11, 2026
earnings_calendar
OVID Q1 2026 Earnings Scheduled — 2026-05-11
Apr 29, 2026
short_volume
Short Volume: OVID — 55.8% short (0.3M / 0.6M)
Short: 320,498 | Exempt: 12,250 | TRF Vol: 574,123 | Short Ratio: 55.8% | Off-exchange volume (dark pool + OTC)
Apr 24, 2026
short_volume
Short Volume: OVID — 61.9% short (0.3M / 0.5M)
Short: 328,872 | Exempt: 0 | TRF Vol: 531,257 | Short Ratio: 61.9% | Off-exchange volume (dark pool + OTC)
Apr 16, 2026
short_volume
Short Volume: OVID — 61.8% short (0.9M / 1.4M)
Short: 884,488 | Exempt: 900 | TRF Vol: 1,432,325 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Apr 15, 2026
short_volume
Short Volume: OVID — 70.0% short (1.3M / 1.9M)
Short: 1,318,777 | Exempt: 25,421 | TRF Vol: 1,884,153 | Short Ratio: 70.0% | Off-exchange volume (dark pool + OTC)